{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:36:18Z","timestamp":1792089378009,"version":"4.4.0"},"reference-count":23,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Prostatic hyperplasia is among the most common urological conditions in ageing men, and transurethral resection of the prostate (TUR-P) has long been the standard surgical treatment. The perioperative mortality rate (POMR) is an important quality indicator for surgical care, yet contemporary national Swedish POMR data associated with TUR-P is lacking.Aims: The primary aim was to assess all-cause mortality up to 90-days following TUR-P in Sweden 2013\u20132022 and whether there was any temporal trend in POMR. The secondary aim was to assess the impact of patients\u2019 characteristics (age, ASA class and indication).Material and Methods: This was an observational, register-based cohort study using data from the Swedish-Perioperative-Register (SPOR). A total of 14,052 TUR-P procedures (KED22) for benign prostatic hyperplasia or prostate cancer were included. Descriptive statistics, ANOVA, chi-square test, and multivariable-logistic regression were applied.Results: A total of 10 patients died within 30-days (0.07%) and 56 within 90-days (0.4%). No difference in annual POMR was seen over the study-period. Increasing age, higher ASA-class and cancer indication were the only independent predictors of 90-day mortality. Patients aged above 80-years had an OR of 7.9 (95% confidence interval [CI]: 2.2\u201342.3), ASA 4 had an OR of 12.6 (95% CI: 1.7\u201394.3), and cancer diagnosis had an OR of 4.4 (95% CI: 2.5\u20137.9) in the multivariable logistic regression. Conclusions: POMR following TUR-P in Sweden is low and numerically similar to age-adjusted background mortality in the Swedish population up to the age of 70-years. High age, ASA-class and cancer diagnosis are the strongest predictors of postoperative mortality.<\/jats:p>","DOI":"10.2340\/sju.v61.46751","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:05:35Z","timestamp":1788264335000},"page":"216-222","source":"Crossref","is-referenced-by-count":1,"title":["All cause 90-day mortality associated with TUR-P procedure: a Swedish quality register-based study (2013\u20132022)"],"prefix":"10.2340","volume":"61","author":[{"given":"Vachik","family":"Petrosyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cronhjort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truls","family":"G\u00e5rdemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"167005","unstructured":"GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev. 2022;3(11):e754\u2013e776."},{"key":"167006","doi-asserted-by":"crossref","unstructured":"Sandhu JS, Bixler BR, Dahm P, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2024;211(1):11\u201319.","DOI":"10.1097\/JU.0000000000003698"},{"key":"167007","doi-asserted-by":"crossref","unstructured":"Cornu JN, Ahyai S, Bachmann A, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67(6):1066\u20131096.","DOI":"10.1016\/j.eururo.2014.06.017"},{"key":"167008","doi-asserted-by":"crossref","unstructured":"Mayer EK, Kroeze SGC, Chopra S, et al. Examining the \u2018gold standard\u2019: a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes. BJU Int. 2012;110(11):1595\u20131601.","DOI":"10.1111\/j.1464-410X.2012.11119.x"},{"key":"167009","doi-asserted-by":"crossref","unstructured":"Cornu JN, Zantek P, Burtt G, et al. Minimally invasive treatments for benign prostatic obstruction: a systematic review and network meta-analysis. Eur Urol. 2023;83(6):534\u2013547.","DOI":"10.1016\/j.eururo.2023.02.028"},{"key":"167010","doi-asserted-by":"crossref","unstructured":"Rassweiler J, Teber D, Kuntz R, et al. Complications of transurethral resection of the prostate (TURP) \u2013 incidence, management, and prevention. Eur Urol. 2006;50(5):969\u2013979; discussion 980.","DOI":"10.1016\/j.eururo.2005.12.042"},{"key":"167011","doi-asserted-by":"crossref","unstructured":"Watters DA, Hollands MJ, Gruen RL, et al. Perioperative mortality rate (POMR): a global indicator of access to safe surgery and anaesthesia. World J Surg. 2015;39(4):856\u2013864.","DOI":"10.1007\/s00268-014-2638-4"},{"key":"167012","doi-asserted-by":"crossref","unstructured":"Davies JI, Gelb AW, Gore-Booth J, et al. Global surgery, obstetric, and anaesthesia indicator definitions and reporting: an Utstein consensus report. PLoS Med. 2021;18(8):e1003749.","DOI":"10.1371\/journal.pmed.1003749"},{"key":"167013","doi-asserted-by":"crossref","unstructured":"Eredics K, Wachabauer D, R\u00f6thlin F, et al. Reoperation rates and mortality after transurethral and open prostatectomy in a long-term nationwide analysis: have we improved over a decade? Urology. 2018;118:152\u2013157.","DOI":"10.1016\/j.urology.2018.04.032"},{"key":"167014","doi-asserted-by":"crossref","unstructured":"Salmivalli A, Ettala O, Bostr\u00f6m PJ, et al. Mortality after surgery for benign prostate hyperplasia: a nationwide cohort study. World J Urol. 2022;40(7):1785\u20131791.","DOI":"10.1007\/s00345-022-03999-0"},{"key":"167015","doi-asserted-by":"crossref","unstructured":"Holmstr\u00f6m B, Enlund G, Spetz P, et al. The Swedish Perioperative Register: description, validation of data mapping and utility. Acta Anaesthesiol Scand. 2023;67(2):233\u2013239.","DOI":"10.1111\/aas.14174"},{"key":"167016","unstructured":"Holmstr\u00f6m B, Enlund G, Frostell C, et al. SPOR covers 100 percent of publicly run surgical care. Lakartidningen. 2024;121:23197."},{"key":"167017","doi-asserted-by":"crossref","unstructured":"Kilhamn N, Eriksson J, von Oelreich E, et al. Age, ASA physical status and surgical outcomes: insights from a nationwide cohort study. Anaesthesia. 2026;81(2):188\u2013200.","DOI":"10.1111\/anae.16723"},{"key":"167018","doi-asserted-by":"crossref","unstructured":"Issmail L, Albert J, Frostell C, et al. All-cause 30-day mortality associated with hysterectomy in Sweden from 2015 to 2021 using data from the Swedish perioperative register. Clin Epidemiol Glob Health. 2024;29:101727.","DOI":"10.1016\/j.cegh.2024.101727"},{"key":"167019","doi-asserted-by":"crossref","unstructured":"Magnusson J, Karlsson J, Sk\u00f6ldenberg O, et al. Difference in early all-cause mortality among patients having hip arthroplasty a Swedish perioperative registry study 2013\u20132022. J Orthop Surg Res. 2024;19(1):295.","DOI":"10.1186\/s13018-024-04752-6"},{"key":"167020","doi-asserted-by":"crossref","unstructured":"Gavria S, Karlsson J, Albert J, et al. Low all-cause 90-day mortality after revision knee arthroplasty: a study based on the Swedish Perioperative Register (SPOR), 2017\u20132022. J Exp Orthop. 2026;13(1):e70682.","DOI":"10.1002\/jeo2.70682"},{"key":"167021","doi-asserted-by":"crossref","unstructured":"Marchioni M, Primiceri G, Veccia A, et al. Transurethral prostate surgery in prostate cancer patients: a population-based comparative analysis of complication and mortality rates. Asian J Urol. 2024;11(1):48\u201354.","DOI":"10.1016\/j.ajur.2022.05.008"},{"key":"167022","doi-asserted-by":"crossref","unstructured":"Marchioni M, Cindolo L, Di Nicola M, et al. Major acute cardiovascular events after transurethral prostate surgery: a population-based analysis. Urology. 2019;131:196\u2013203.","DOI":"10.1016\/j.urology.2019.05.014"},{"key":"167023","doi-asserted-by":"crossref","unstructured":"Patel HD, Ball MW, Cohen JE, et al. Morbidity of urologic surgical procedures: an analysis of rates, risk factors, and outcomes. Urology. 2015;85(3):552\u2013559.","DOI":"10.1016\/j.urology.2014.11.034"},{"key":"167024","doi-asserted-by":"crossref","unstructured":"Sankar A, Johnson SR, Beattie WS, et al. Reliability of the American Society of Anesthesiologists physical status scale in clinical practice. Br J Anaesth. 2014;113(3):424\u2013432.","DOI":"10.1093\/bja\/aeu100"},{"key":"167025","doi-asserted-by":"crossref","unstructured":"Salmivalli A, Bostr\u00f6m P, Nurminen P, et al. National trends of surgery for benign prostatic hyperplasia in Finland. Scand J Urol. 2024;59:70\u201375.","DOI":"10.2340\/sju.v59.32425"},{"key":"167026","doi-asserted-by":"crossref","unstructured":"Arch A, Thamsborg A, Winck-Flyvholm L, et al. Thermo-expandable intraprostatic nitinol stents in the treatment of bladder outlet obstruction: a consecutive case series. Scand J Urol. 2024;59:169\u2013172.","DOI":"10.2340\/sju.v59.41991"},{"key":"167027","doi-asserted-by":"crossref","unstructured":"Bjarnason J, Ingimarsson JP, Thorisson H, et al. Prostate artery embolization for benign prostatic hyperplasia: a retrospective single-center study of clinical outcome. Scand J Urol. 2025;60:130\u2013134.","DOI":"10.2340\/sju.v60.44137"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/46751\/55320","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/46751\/55320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:05:41Z","timestamp":1788264341000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/46751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":23,"URL":"https:\/\/doi.org\/10.2340\/sju.v61.46751","relation":{},"ISSN":["2168-1813"],"issn-type":[{"value":"2168-1813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}